Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05546411 · ClinicalTrials.gov registry record · Phase 2
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
A Phase 2 study, sponsored by Kimberly Perez, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05546411 is a Phase 2 study that was terminated before completion, run by Kimberly Perez, MD. The registered enrollment target is 8 participants.
The verdict
NCT05546411, a Phase 2 study, was terminated before completion, sponsored by Kimberly Perez, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is being done to evaluate the safety and efficacy of adding NIS793 to standard of care FOLFIRINOX treatment for pancreatic cancer. The names of the study interventions involved in this study are: * NIS793 * FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluorouracil, Irinotecan, and Oxaliplatin) Other interventions may include: * Chemoradiation Therapy * Surgery
Interventions
- DRUG Leucovorin
- DRUG 5-Fluorouracil (5-FU)
- DRUG Oxaliplatin
- DRUG mFOLFIRINOX
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-01-06 |
| Est. Completion | 2023-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05546411
The ClinicalTrials.gov registry entry for NCT05546411 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kimberly Perez, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Leucovorin is the first listed.
NCT05546411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05546411 about?
NCT05546411 is a clinical study titled "A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer". This study is being done to evaluate the safety and efficacy of adding NIS793 to standard of care FOLFIRINOX treatment for pancreatic cancer. The names of the study interventions involved in this study are: * NIS793 * FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluorouracil, Irinotecan, and Oxaliplatin...
What is the current status of trial NCT05546411?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2023-01-06. Estimated completion is 2023-10-13.
What interventions are being tested in trial NCT05546411?
The interventions under investigation include: Leucovorin (DRUG), 5-Fluorouracil (5-FU) (DRUG), Oxaliplatin (DRUG), mFOLFIRINOX (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT05546411?
This trial is sponsored by Kimberly Perez, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.